Loading stock data…
InflaRx N.V (IFRX)
$2.28+0.36 (+18.75%)
After Hours$2.24-0.04 (-1.75%)· Last close Jun 29
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
InflaRx N.V. in the Healthcare sector is trading at $2.28 with a market capitalization of $228M. Wall Street consensus targets $7.79 (7 analysts), implying a +241.6% move over the next 12 months. The stock is currently 23% below its 52-week high of $2.95, remaining 68.9% above its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +241.6% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0↑ | -$33,931↓ | $23,830↓ | $39,432 | $0 |
| Gross Profit | $0↑ | -$4.89M↓ | $23,497↑ | -$2.36M↓ | -$9,291 |
| Operating Income | -$7.21M↑ | -$12.86M↓ | -$9.48M↑ | -$12.83M↑ | -$13.01M |
| Net Income | -$5.59M↑ | -$10.64M↑ | -$12.26M↑ | -$14.42M↓ | -$8.31M |
Peer Comparison
JNJUNHPFE
Fundamentals
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory dis...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$228.30M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-116.32%
Volume
Today's trading volume
6.79M
Recent News
Strength Seen in Kymera Therapeutics (KYMR): Can Its 16.6% Jump Turn into More Strength?
Kymera Therapeutics (KYMR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
What Do Analysts Say About InflaRx N.V. (IFRX)?
While InflaRx N.V. (NASDAQ:IFRX) has gained 82.18% year-to-date, analysts continue to see 385.90% upside, helping it secure a spot on our list of hot biotech stocks under $5 to buy. That analyst conviction only strengthened by mid-May, with two firm upgrades and target raises arriving back-to-back following a corporate update and first-quarter results. On May […]
Here’s Why InflaRx (IFRX) is Among the 10 Most Volatile Penny Stocks to Buy Now
InflaRx N.V. (NASDAQ:IFRX) is one of the 10 Most Volatile Penny Stocks to Buy Now. On May 13, 2026, Raymond James upgraded InflaRx N.V. (NASDAQ:IFRX) to Strong Buy from Outperform with a price target of $9, up from $7. Raymond James said sentiment is increasingly supported by a constructive view of InflaRx’s izicopan program in […]
InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline
InflaRx (NASDAQ:IFRX) outlined plans to prioritize development of izicopan, an oral inhibitor of the C5a receptor (C5aR), in ANCA-associated vasculitis (AAV) and other renal diseases during a company conference call led by CEO and founder Niels Riedemann. Izicopan positioned as a next-generation C5
InflaRx N.V. (IFRX) Regains Compliance With Nasdaq
InflaRx N.V. (NASDAQ:IFRX) is one of the top 10 hot penny stocks to buy now. InflaRx N.V. (NASDAQ:IFRX) announced on April 28 that it received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC on April 27, informing management that the company regained compliance with Nasdaq’s minimum bid price requirement […]